The chemical industry recognises the need to address the principles of sustainability and there is an urgent need to design processes as new paradigms in modern manufacturing residues or, if unavoidable, to recycle them. However, sustainability also requires the design of chemical processes that minimise the use of energy and direct the reaction towards the desired products, i.e. high selectivity at the required conversion with minimum energy consumption. Catalysis must be at the core of any new chemical process and the development of active, stable, and selective catalysts will be key for chemical sustainability. Most industrial chemical processes involve several chemical steps and each step often uses a different catalyst. Product separation and purification between each step also requires further equipment and energy consumption and hence it is highly beneficial to simplify the overall process. In this project, we aim to minimise the number of individual steps in chemical processes by tandem reactions with multifunctional heterogeneous catalytic systems that can perform the consecutive chemical reactions in one reaction, and we will achieve this using microchannel reactors. Moreover, we aim to achieve this for the preparation of key platform chemicals e.g. acetic acid is a major chemical intermediate that currently require several chemical process steps. The main objective of this project is to design and develop multifunctional catalysts combined with a microchannel structured reactor to convert methane into value-added oxygenate products including methanol and acetic acid via a tandem oxidative carbonylation process. The use of tandem heterogeneous catalysis represents an exceptionally novel approach to both catalyst and reaction design. We will explore the use of microchannel reactors for methane oxidation/carbonylation. Catalyst synthesis will be coupled with this reactivity testing and catalyst design will be driven by the reactor data. Catalysts will be characterised using state-of-the-art techniques. The engineering and science will operate in an iterative manner with each new step informing the overall programme. What will success look like? Success will be the demonstration of the potential of a bespoke combination of a microchannel reactor coupled with multifunctional catalysts, generating enhanced performance that could lead to a paradigm shift in the synthesis and application of catalytic tandem reactions.

Humanity faces critical global challenges in supplying clean energy, food, medicines and materials for a population forecast to reach 10 billion by 2050. Chemical synthesis will play a central role in addressing these challenges, as organic molecules are the fundamental building blocks of drugs, agrochemicals, and materials. However, the synthesis of most chemicals remains energy intensive, requiring fossil fuel feedstocks and endangered metal catalysts, and produces huge levels of waste - far from what is needed for a net-zero future. The essential transition to a circular chemistry economy will materialise only with a total re-think of organic synthesis: a 'Chemical Revolution' is urgently needed, for which Industry users will require a 'next generation' of suitably trained graduates. Without such change, the chemical industry will not be able to sustain the necessary pace of innovation in new chemical technologies, in the face of rapidly changing chemical regulation and policy, thus rendering this CDT crucial for the future of UK PLC. The Oxford-York ESPRC CDT in Chemical Synthesis for a Healthy Planet will deliver world-leading, ground-breaking training to a next generation of synthetic chemists, developing a sustainable, innovative chemistry culture that equips them to address major emerging and future global challenges in Human Health, Energy and Materials, and Food Security. In doing so, we meet a critical User Need, by supplying the workforce that is essential to create the innovative solutions UK chemical industries urgently require. Our overarching objective is to train students to supersede current practices for the synthesis of functional organic molecules by developing sustainable, field-advancing synthetic pathways to the complex targets needed in drug discovery, agrochemistry, and materials development. Our student cohorts will work together in a training period at both Oxford and York, before engaging with industry co-supervised projects in four research fields that develop innovative, sustainable transformations and synthetic strategies, and apply them in pharma, agro and materials chemistry contexts. With around a third of projects supervised jointly at Oxford and York, we will ensure a strong cross-institute connection; whole programme meetings and research field seminars will enable students across multiple cohorts to contribute to and elevate each others' science. Our association with the Eur1.25bn Center for the Transformation of Chemistry brings a unique connection for our students to a major initiative that is aiming to revolutionise chemical synthesis, as well its >140 chemical organisations across Europe. Our partnership with >10 SMEs and their Entrepreneurs-in-Residence will develop entrepreneurial skills and ensure students are exposed to the cutting-edge of chemical innovation in UK PLC. The applications and benefits from the CSHP CDT are many: Primarily, we will develop a UK-wide network of sustainably-minded, innovative chemists ready to meet the urgent User Needs of the UK chemical industry, bolstering this major sector of UK PLC. The scientists graduating from the CSHP CDT, the high-level science they produce, along with the related tools and technologies, will all contribute to the UK's ambitions as a Physical and Mathematical Sciences Powerhouse. We will set new benchmarks for graduate training by ensuring sustainability is embedded and visible in all research and its outputs, as well as influencing and connecting to graduates across the UK through biennial symposia. Our cohorts' work as Sustainability Ambassadors will permeate our exciting discoveries and the message of the future role of synthetic chemistry throughout society - from school to the general public. Above all, we believe this rigorous and inspirational programme is utterly essential if the UK is to remain globally competitive in the rapidly evolving chemistry landscape.

The EPSRC Centre for Doctoral Training in Statistics and Machine Learning (StatML) will address the EPSRC research priority of the 'physical and mathematical sciences powerhouse' through an innovative cohort-based training program. StatML harnesses the combined strengths of Imperial and Oxford, two world-leading institutions in statistics and machine learning, in collaboration with a broad spectrum of industry partners, to nurture the next generation of leaders in this field. Our students will be at the forefront of advancing the core methodologies of data science and AI, crucial for unlocking the value inherent in data to benefit industry and society. They will be equipped with advanced research, technical, and practical skills, enabling them to make tangible real-world impacts. Our students will be ethical and responsible innovators, championing reproducible research and open science. Collaborating with students, charities and equality experts, StatML will also pioneer a comprehensive strategy to promote inclusivity, attract individuals from diverse backgrounds and eliminate biases. This will help diversify the UK's future statistics and machine learning workforce, essential for ensuring data science is used for public good. Data science and AI are now part of our everyday lives, transforming all sectors of the economy. To future-proof the UK's prosperity and security, it is essential to develop new methodology, specifically tailored to meet the big societal challenges of the future. The techniques underpinning such methods are founded in statistics and machine learning. Through close collaboration with a broad range of industry partners, our cohort-based training will support the UK in producing a critical mass of world-leading researchers with expertise in developing cutting-edge, impactful statistical and machine learning methodology and theory. It is well documented in government and learned society reports that the UK economy has an urgent need for these people. The significant level of industry support for our proposal also highlights the necessity of filling this gap in the UK data science ecosystem. StatML will learn from and build upon our previous successful experiences in cohort training of doctoral students (our existing StatML CDT funded in 2018, as well as other CDTs at Imperial and Oxford). Our students will continue to produce impactful, internationally leading research in statistics and machine learning (as evidenced by our students' impressive publication record and our world-leading research environment, as rated by the REF 2021 evaluation), while complementing this with a bespoke cohort-based Advanced Training program in Statistics and Machine Learning (StatML-AT). StatML-AT has been developed from our experience and in partnership with industry. It will be responsive to emerging technologies and equip our students with the practical skills required to transform how data is used. It will be delivered by our outstanding academics from both institutions alongside with industry leaders to ensure that students receive training in cutting edge technologies, along with the latest ideas in ethics, responsible innovation, sustainability and entrepreneurship. This will be complemented by industrial and academic placements to allow the students to develop their own international network and produce high-impact research. Together, StatML and its partners will train 90+ students over 5 cohorts. More than half of these will be funded from external sources, including 25+ by industry, representing excellent value for money. Our diverse cohorts will benefit from a unique and responsive training program combining academic excellence, industry engagement, and interdisciplinary culture. This will make StatML a vibrant research environment inspiring the next methodological advancements to transform the use of data and AI across industry and society.

Chemical biology is spearheading the development & translation of novel molecular tools and technologies to study biology and develop biomedical understanding. Dovetailing these platforms with industry 4.0/5.0 breakthroughs in automation & robotics, artificial intelligence & machine learning, the CDT will unlock the Lab of the Future paradigm. This will redefine the state of the art with respect to making, measuring, modelling & manipulating molecular interactions in biological systems, leading to novel R&D workflows, promoting efficient design-test cycles and driving sustainability. These molecular technologies will (i) enable biological & medical research, (ii) revolutionise understanding of disease & (iii) create novel diagnostics, drugs & therapies, focusing increasingly on individual patient outcomes. They will also impact the agri-tech sector which faces huge demand to increase productivity by unlocking strategies to e.g. track agrochemicals in plants/soil, understand modes of action & drive precision farming. Similarly, advances in personal care industrial processes are critically dependent on development of molecular technologies to gain insight into structured product design. The application of novel molecular tools/technologies, Lab of the Future strategies & their commercialisation through the instrumentation science sector is thus critical to the UK economy, supporting >4,500 healthcare, personal care, agri-science & biotech companies. This will transform (i) therapeutic, agrochemical & personal care product discovery (ii) med-tech/biotech/healthcare instrumentation R&D pipelines & (iii) stimulate creation of SMEs. Working closely with civic partners including Hammersmith & Fulham Council and the NHS, the CDT's talent & research pipeline will act as a growth engine for one of the most rapidly expanding Life Science ecosystems in Europe, the White City Innovation District. Given the importance of Chemical Biology to UK plc there is great demand but short supply of Chemical Biology PhD graduates able to match the pace of innovation across the physical/life science interface, at a time when industry & health sectors need these skills to accelerate productivity. The CDT in Chemical Biology: Empowering UK BioTech innovation with its unique 5 year programme: 1 year MRes + 3 year PhD + 1 year ELEVATE Fellowship directly addresses this skills gap by training a new generation of career-ready graduates, able to embrace the Lab of the Future concept and unlock its potential by fusing innovative molecular tools & tech with industry 4.0 & 5.0 advances to study molecular interactions & develop applications in the life science, agriscience & personal care sectors. CDT students will benefit from a research and training programme created with >100 industry/external stakeholders designed to meet future employer's needs. Our cohort-based programme with EDI at its heart, will allow students to contextualise their work within wider CDT activities & find novel solutions to their research, supported by one of the world's largest Chemical Biology communities: the Institute of Chemical Biology (>165) research groups. Students will be trained in multidisciplinary blue skies/translational research, lean innovation, scale fast/fail fast approaches, creating scientists able to understand molecular technologies, sustainable product design, early-stage commercialisation, & industry's pace of change. To support this, our training includes Future Lab & HackEDU courses (prototyping training), a drug screening programme, Biz-Catalyst (entrepreneurial training), InnovaLab (SME accelerator), a Data Science course, Human Centred Design, Science Communication (with BBC) & Bioethics/RRI/Sustainability/Policy courses. Following PhD completion, students can enter the ELEVATE fellowship programme, bridging the gap between PhD & industry/academia, offering training, personalised workplace opportunities & enable students to kickstart new companies.

The pharmaceutical, chemical and polymer industries are cornerstones of Europe's economy. A key element for their transition to more sustainable processes and to innovative new compounds is biocatalysis. Of particular interest are metallo-enzymes, i.e. proteins that host a metal cofactor. They catalyze a multitude of redox and radical reactions. To access reactions that are unknown in nature, artificial metallo-enzymes can be created. They combine the new-to-nature catalytic activity of metal complexes with the selectivity-inducing environment of the active protein site. To develop novel biocatalysts, a highly interdisciplinary skill set is needed. MetRaZymes will create a PhD school across leading European universities that will train the next generation of scientists capable of tackling the design, development and implementation of novel enzymatic reactions in a holistic approach. It brings together computational bioscientists, bioinorganic and polymer chemists, and bioprocess engineers. Using artificial and repurposed metalloenzymes as the focal point, the ESRs will develop novel biocatalysts for radical reactions of high synthetic value, such as the late stage modification of pharmaceutical intermediates or the synthesis of polymers from renewable monomers. To train the ESRs in the needs of industrial biotechnology, the consortium includes eight of Europe's leading pharmaceutical, chemical and enzymology companies. The ESRs will benefit from a vast transferable skills training program delivered by five training partners. Highlights include a Nature Masterclass and Wikipedia workshop. Communication partners such as Wikimedia and the Industrial Biotechnology Innovation Centre will act as muliplicators for the communication of results. Moreover, the ESRs will work with artist that use biology as their way of expression to create an ARTzymes exhibition that will foster the ERS's creativity and result in a an unique form of science dialogue with the general public